JP2008518020A - 創傷治癒を促進する方法 - Google Patents
創傷治癒を促進する方法 Download PDFInfo
- Publication number
- JP2008518020A JP2008518020A JP2007539081A JP2007539081A JP2008518020A JP 2008518020 A JP2008518020 A JP 2008518020A JP 2007539081 A JP2007539081 A JP 2007539081A JP 2007539081 A JP2007539081 A JP 2007539081A JP 2008518020 A JP2008518020 A JP 2008518020A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- wound
- mammal
- administered
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000029663 wound healing Effects 0.000 title claims abstract description 13
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 29
- 206010052428 Wound Diseases 0.000 claims abstract description 27
- 102100024304 Protachykinin-1 Human genes 0.000 claims abstract description 15
- 101800003906 Substance P Proteins 0.000 claims abstract description 15
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims abstract description 14
- 208000004210 Pressure Ulcer Diseases 0.000 claims abstract description 3
- 208000002847 Surgical Wound Diseases 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 41
- 241000124008 Mammalia Species 0.000 claims description 15
- 230000005855 radiation Effects 0.000 claims description 11
- OUPXSLGGCPUZJJ-SARDKLJWSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfonyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)N(C)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 OUPXSLGGCPUZJJ-SARDKLJWSA-N 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 5
- UFBNSKYNZDUWSN-RZGVDQIZSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan Chemical compound CSCC[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)CC1=CC=CC=C1 UFBNSKYNZDUWSN-RZGVDQIZSA-N 0.000 claims description 4
- MSKLWPIJUANGPO-CUZNLEPHSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 MSKLWPIJUANGPO-CUZNLEPHSA-N 0.000 claims description 4
- ZEPTUBCWHRSMIP-UHFFFAOYSA-N 2-[[1-[6-amino-2-[[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[5-amino-1-[[1-[[1-[[2-[[1-[(1-amino-1-oxohexan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3 Chemical compound C=1C=CC=CC=1CC(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1N(CCC1)C(=O)C(CCCCN)NC(=O)C1N(CCC1)C(=O)C(N)CCCN=C(N)N)C(=O)NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCCC)C(N)=O)CC1=CC=CC=C1 ZEPTUBCWHRSMIP-UHFFFAOYSA-N 0.000 claims description 4
- CMARLNZAQITWSL-UHFFFAOYSA-N 2-[[1-[6-amino-2-[[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[5-amino-1-[[1-[[1-[[2-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoeth Chemical compound C=1C=CC=CC=1CC(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1N(CCC1)C(=O)C(CCCCN)NC(=O)C1N(CCC1)C(=O)C(N)CCCN=C(N)N)C(=O)NC(C(=O)N(C)CC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(N)=O)CC1=CC=CC=C1 CMARLNZAQITWSL-UHFFFAOYSA-N 0.000 claims description 4
- XHWDVRRNQHMAPE-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[5-amino-2-[[5-amino-2-[[1-[6-amino-2-[[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpro Chemical compound C=1C=CC=CC=1CC(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1N(CCC1)C(=O)C(CCCCN)NC(=O)C1N(CCC1)C(=O)C(N)CCCN=C(N)N)C(=O)NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(O)=O)CC1=CC=CC=C1 XHWDVRRNQHMAPE-UHFFFAOYSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 230000003872 anastomosis Effects 0.000 claims description 2
- 238000004880 explosion Methods 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000005865 ionizing radiation Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 206010056340 Diabetic ulcer Diseases 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62201504P | 2004-10-27 | 2004-10-27 | |
| PCT/US2005/038646 WO2006047625A2 (en) | 2004-10-27 | 2005-10-25 | Method to promote wound healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518020A true JP2008518020A (ja) | 2008-05-29 |
| JP2008518020A5 JP2008518020A5 (enExample) | 2008-12-04 |
Family
ID=36228442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539081A Pending JP2008518020A (ja) | 2004-10-27 | 2005-10-25 | 創傷治癒を促進する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080318869A1 (enExample) |
| EP (1) | EP1809313A4 (enExample) |
| JP (1) | JP2008518020A (enExample) |
| AU (1) | AU2005299341A1 (enExample) |
| CA (1) | CA2585265A1 (enExample) |
| WO (1) | WO2006047625A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101621149B1 (ko) | 2014-07-09 | 2016-05-16 | 계명대학교 산학협력단 | 만성 창상용 동물 모델 |
| WO2017175909A1 (ko) * | 2016-04-07 | 2017-10-12 | 주식회사 바이오솔루션 | 물질 p를 포함하는 상처치유용 약학 조성물 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
| WO2018014016A1 (en) * | 2016-07-15 | 2018-01-18 | New Amsterdam Sciences | Substance and method for treating radiation exposure |
| CN111182887A (zh) * | 2017-06-14 | 2020-05-19 | 株式会社生物解决方案有限公司 | 用于改善皮肤皱纹或抗炎活性的包括物质p的化妆品组合物 |
| KR102158969B1 (ko) * | 2018-10-19 | 2020-09-23 | 주식회사 바이오솔루션 | 물질 p를 포함하는 난치성 궤양 치료용 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616562A (en) * | 1990-04-27 | 1997-04-01 | Murphy; Christopher J. | Methods and compositions using substance P to promote wound healing |
| JP2002226395A (ja) * | 2000-08-10 | 2002-08-14 | Teruo Nishida | 皮膚創傷治癒促進剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945508A (en) * | 1996-07-23 | 1999-08-31 | Witten; Mark L. | Substance P treatment for immunostimulation |
| WO2002013853A1 (en) * | 2000-08-10 | 2002-02-21 | Santen Pharmaceutical Co., Ltd. | Skin wound healing promoters |
| WO2004058155A2 (en) * | 2002-12-18 | 2004-07-15 | Witten Mark L | Stimulation of hair regrowth |
| US20070154448A1 (en) * | 2005-11-22 | 2007-07-05 | Ted Reid | Methods and compositions using Substance P to promote wound healing |
-
2005
- 2005-10-25 AU AU2005299341A patent/AU2005299341A1/en not_active Abandoned
- 2005-10-25 US US11/666,474 patent/US20080318869A1/en not_active Abandoned
- 2005-10-25 EP EP05813067A patent/EP1809313A4/en not_active Withdrawn
- 2005-10-25 CA CA002585265A patent/CA2585265A1/en not_active Abandoned
- 2005-10-25 JP JP2007539081A patent/JP2008518020A/ja active Pending
- 2005-10-25 WO PCT/US2005/038646 patent/WO2006047625A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616562A (en) * | 1990-04-27 | 1997-04-01 | Murphy; Christopher J. | Methods and compositions using substance P to promote wound healing |
| JP2002226395A (ja) * | 2000-08-10 | 2002-08-14 | Teruo Nishida | 皮膚創傷治癒促進剤 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101621149B1 (ko) | 2014-07-09 | 2016-05-16 | 계명대학교 산학협력단 | 만성 창상용 동물 모델 |
| WO2017175909A1 (ko) * | 2016-04-07 | 2017-10-12 | 주식회사 바이오솔루션 | 물질 p를 포함하는 상처치유용 약학 조성물 |
| JP2018524405A (ja) * | 2016-04-07 | 2018-08-30 | バイオソリューション カンパニー・リミテッドＢｉｏ Ｓｏｌｕｔｉｏｎ Ｃｏ Ｌｔｄ | 物質ｐを含む傷治癒用薬学組成物 |
| US10596224B2 (en) | 2016-04-07 | 2020-03-24 | Biosolutions Co., Ltd | Method of treating a wound, comprising the step of administering a composition including a substance P |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006047625A2 (en) | 2006-05-04 |
| WO2006047625A3 (en) | 2006-07-27 |
| AU2005299341A1 (en) | 2006-05-04 |
| EP1809313A4 (en) | 2008-01-23 |
| EP1809313A2 (en) | 2007-07-25 |
| CA2585265A1 (en) | 2006-05-04 |
| US20080318869A1 (en) | 2008-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dunn | Psychoneuroimmunology, stress and infection | |
| KR20210108979A (ko) | 부적응 통증을 치료하기 위한 레시니페라톡신의 신경 주위 투여 | |
| Straube et al. | Studies with cysteinamine and cysteine in x-irradiated animals | |
| Cao et al. | The involvement of SDF-1α/CXCR4 axis in radiation-induced acute injury and fibrosis of skin | |
| US9272013B2 (en) | Methods for treating combined radiation and thermal injury | |
| JP2008518020A (ja) | 創傷治癒を促進する方法 | |
| JP6150374B2 (ja) | 放射線被ばく治療剤及び放射線被ばく治療方法 | |
| EP2718456B1 (en) | Mitigation of cutaneous injury with il-12 | |
| US10639296B2 (en) | Methods to mitigate injury from radiation exposure | |
| zur Behandlung | Effectiveness of salicylic acid paste for treatment of digital dermatitis in dairy cows compared with tetracycline spray and hydrotherapy | |
| US20230270739A1 (en) | Methods and Compositions for Treating Pain While Minimizing the Risk of Opioid Addiction | |
| Mazarati et al. | Felbamate in experimental model of status epilepticus | |
| Miyachi et al. | Low-dose X-ray-induced depression of sexual behavior in mice | |
| Tadjalli et al. | Skin graft survival after external beam irradiation | |
| JP2008518020A5 (enExample) | ||
| AU2445900A (en) | Regulation of anaesthesia | |
| CA3176457A1 (en) | Therapeutic strategies to manage facial contractures post injury | |
| RU2248210C1 (ru) | Способ регенерации костной ткани в эксперименте | |
| Maiti et al. | The mitogenic action of prolactin on some endocrine organs of chicks | |
| Easter | How to select cases and use autologous conditioned serum to treat proximal suspensory desmitis. | |
| US20250281486A1 (en) | Therapeutic strategies to manage facial contractures post injury | |
| Spadavecchia et al. | Transdermal Fentanyl Uptake at Two Different Patch Locations in Swiss White Alpine Sheep | |
| Bergh et al. | Defocused CO2 laser therapy in traumatic arthritis of the metacarpophalangeal joint: A randomized clinical study | |
| BRUCE | Factors Controlling the Initiation and Cessation of Early Events in the Regenerative Process¹ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081020 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081020 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110414 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110921 |